Diary - News All news Tollys welcomes Dr. Jean-Pierre Armand as member of its scientific advisory board

Tollys welcomes Dr. Jean-Pierre Armand as member of its scientific advisory board

Professor Jean-Yves Blay, current member of the scientific
advisory board, takes up chairmanship as company prepares to
launch clinical programs

Lyon, France, March 9, 2021 — Tollys, a biopharmaceutical company developing TL532, the first synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, today announces that Dr. Jean-Pierre Armand will be joining its scientific advisory board and that Professor Jean-Yves Blay has been appointed as the board's chairman. The strengthening of this advisory body brings the company one step closer to its first phase I clinical trials, which are planned for 2022.

“We are delighted to welcome Dr. Jean-Pierre Armand to our scientific advisory board,” said Vincent Charlon, CEO of Tollys. “As a specialist in oncology, Jean-Pierre is a valuable addition to our scientific team, especially with the first clinical trials for our candidate drug TL-532 in mind; a key stage in our development. The nomination of Professor Jean-Yves Blay as chairman of the scientific advisory board confirms that the company is well on its way towards entering the clinical phase.”